Loading…
Beijing state pharma trading group with licensed rights to export and import narcotic and controlled pharmaceutical ingredients.
Beijing state pharma trading group with licensed rights to export and import narcotic and controlled pharmaceutical ingredients.
Most of the volume is distributing medicines and trading drug materials on thin margins, while the licence to handle controlled narcotic ingredients gives it a protected niche in trade of those materials. It is part of a central state-owned group.
In one line: A Chinese state-licensed controlled-substance trader.
Moat: narrow (regulatory licence). One of very few companies licensed by the state to trade controlled narcotic pharmaceutical ingredients.
Headquarters: Beijing, China · Employees: 7,949
Size China Meheco (600056.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.00B, the 1261st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.93 on 6 Nov 2026.
Performance Over six months the shares fell 13.8%, against -1.5% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 1.5% over the last twelve months (peer median +8.1%); the operating margin is 3.1% (peer median 15.5%).
Valuation It trades at 0.6× enterprise value to sales against a peer median of 3.5× (cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.0 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥34.5B | CN¥35.3B | CN¥35.2B | CN¥38.7B | CN¥37.5B |
| Revenue growth | — | 0% | -9% | +3% | — |
| Gross profit | CN¥3.78B | CN¥3.29B | CN¥3.40B | CN¥3.92B | CN¥4.40B |
| EBITDA | n/a | CN¥1.86B | CN¥1.73B | CN¥1.76B | CN¥1.83B |
| Net income | CN¥310M | CN¥473M | CN¥583M | CN¥1.05B | CN¥736M |
| Free cash flow | CN¥843M | CN¥1.09B | CN¥654M | CN¥497M | CN¥1.42B |
| Capital expenditure | CN¥304M | CN¥333M | CN¥359M | CN¥363M | CN¥229M |
| Total debt | CN¥8.78B | CN¥8.49B | CN¥8.06B | CN¥7.05B | CN¥6.68B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| China Meheco 600056.SS | $2.00B | -14% | +2% | 3% | 0.6× | -0.8% |
| Sinopharm 1099.HK | $6.83B | -4% | +3% | 3% | 0.3× | -8.1% |
| Shanghai Pharmaceuticals 601607.SS | $8.32B | -2% | +4% | 3% | 0.3× | -10.0% |
| Jointown Pharmaceutical 600998.SS | $3.96B | +1% | +9% | 2% | 0.4× | 0.1% |
| China Resources Pharmaceutical 3320.HK | $3.74B | -11% | +8% | 4% | 0.6× | -5.3% |
| Nanjing Pharmaceutical 600713.SS | $1.03B | +1% | +3% | 2% | 0.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600056.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.6% | +0.5% | 8th lowest of 21 |
| 6-month return | -13.8% | -1.5% | 5th lowest of 21 |
| Distance from 52-week high | -25.9% | -19.5% | 8th lowest of 21 |
| Revenue growth (TTM) | +1.5% | +8.1% | 10th lowest of 21 |
| Operating margin | 3.1% | 15.5% | 4th lowest of 21 |
| EV / Sales | 0.6× | 3.5× | cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -0.8% | 2.1% | 9th least demanding of 20 |
| Growth delivered (Del g) | -2.1% | +7.1% | 2nd lowest of 20 |
| Hurdle (Req g minus delivered) | +1.3 pp | -9.1 pp | 6th most demanding of 20 |
| ROIC minus cost of capital | +0.0 pp | +2.7 pp | 6th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | 0.6× | -0.8% | -2.1% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 1.3× | -3.0% | +4.4% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | 3.6× | 5.3% | +10.4% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 3.3× | 23.5% | +10.6% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 3.9× | -2.5% | +11.6% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | 4.2× | -1.1% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 1.0× | -6.7% | +3.9% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 1.6× | -8.3% | +5.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 3.4× | 4.5% | +60.2% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 2.0× | 5.1% | +0.6% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 4.4× | -2.2% | +5.5% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 18.9× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 2.7× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 3.3× | 2.1% | +26.7% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | 8.6× | 5.2% | +1.0% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 4.4× | 11.4% | -3.9% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 2.0× | -14.5% | +5.9% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 9.3× | 34.7% | +5.9% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 7.2× | 0.9% | +15.5% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 5.1× | 14.1% | +62.3% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 1.0× | -2.0% | +7.1% |